Content about Genzyme

March 22, 2013
Genzyme drug shows improvement in MS patients

Disease relapse rates and worsening of disability were low among patients taking a drug made by Genzyme for multiple sclerosis, the company said.

January 30, 2013
FDA approves Genzyme drug for rare cholesterol disorder

The Food and Drug Administration has approved a new drug for treating a rare cholesterol disorder, the agency said.

January 28, 2013
FDA accepts application for Genzyme MS drug

The Food and Drug Administration has accepted a regulatory approval application from Genzyme for an experimental treatment for multiple sclerosis, the company said Monday.

October 2, 2012
Genzyme drug for Gaucher disease reduces enlarged spleen size in trial

An experimental drug for treating a rare genetic disease appears effective, according to a late-stage clinical trial.

September 13, 2012
FDA approves new MS drug

The Food and Drug Administration has approved a new drug for multiple sclerosis.

September 4, 2012
Impax settles with Genzyme over kidney dialysis drugs

Generic drug maker Impax Labs has settled with a subsidiary of Sanofi regarding generic versions of two drugs for dialysis patients, Impax said Tuesday.

August 27, 2012
Genzyme provides update on Lemtrada filing with FDA

Genzyme announced it has received a refuse-to-file letter from the Food and Drug Administration in response to the drug maker's supplemental biologics license application for the approval of Lemtrada (alemtuzumab) as a treatment for relapsing multiple sclerosis.

July 31, 2012
Abon seeks approval for generic leukemia drug

Abon Pharmaceuticals is challenging the patent protection on an injected drug used to treat leukemia in children and adolescents, the company said Tuesday.

June 12, 2012
Genzyme seeks regulatory approval for Lemtrada

A Sanofi company is seeking regulatory approval from the Food and Drug Administration for a drug designed to treat relapsing multiple sclerosis.

May 3, 2012
Orphan drugs to see growth through 2018, report finds

Drug makers could strike big with new treatments for rare diseases, according to a new report by a market research firm.

April 20, 2012
Genzyme to present MS drug trials

Drug maker Genzyme plans to present data from trial programs of two multiple sclerosis drugs at the American Academy of Neurology's annual meeting in New Orleans, which starts this Saturday and lasts until next Saturday.

January 24, 2012
FDA OKs Genzyme plant in Massachusetts

The Food and Drug Administration has approved a new manufacturing plant that will be operated by drug maker Genzyme.

December 21, 2011
Genzyme reports lackluster results in MS drug trial

An orally administered drug made by Genzyme for treating multiple sclerosis did not appear superior to a biotech drug already on the market, according to results of a late-stage clinical trial.

November 14, 2011
Genzyme announces phase-3 results of Lemtrada in patients with relapsing MS

A late-stage clinical trial of a drug under development as a treatment for multiple sclerosis has shown "successful" results.

November 10, 2011
Genzyme names leaders of MS, rare diseases units

Genzyme has named leaders of two units that are part of the core focus of the drug maker's business.

October 25, 2011
Sanofi appoints David Meeker as CEO of Genzyme

Sanofi has appointed David Meeker as CEO of Genzyme, the French drug maker said.

October 11, 2011
Inspiration Biopharmaceuticals appoints former Genzyme exec as CEO

A drug maker that focuses on treatments for hemophilia has named a new CEO.

September 15, 2011
GSK, Amicus start phase-3 trial of Fabry disease drug

GlaxoSmithKline and Amicus Therapeutics have started a late-stage clinical trial for a drug to treat a rare genetic disorder, the companies said.

June 30, 2011
Impax settles patent litigation relating to Welchol products

Impax Labs has agreed not to market a generic version of a drug designed to reduce blood sugar and cholesterol in tablet form until 2015.

April 11, 2011
Sanofi-Aventis closes Genzyme acquisition

Genzyme now officially is a wholly owned subsidiary of Sanofi-Aventis.

April 4, 2011
Sanofi-Aventis completes Genzyme acquisition

Sanofi-Aventis said it completed its exchange offer for drug maker Genzyme, which expired just before midnight April 1.

March 7, 2011
Genzyme's board recommends shareholders OK Sanofi offer

The board of directors of Genzyme unanimously recommended that shareholders accept French drug maker Sanofi-Aventis’ $74-per-share buyout offer, Genzyme said Monday.

February 18, 2011
NewsBytes on WAG's Rx purchasing team, WMT's Duncan Mac Naughton, CVS Q4 results and more

DEERFIELD, Ill. — Walgreens this month rounded out the pharmacy purchasing team led by Jeff Berkowitz, who joined the company in the fall as SVP pharmaceutical development and market access.


February 16, 2011
Sanofi-Aventis obtains Genzyme for $20.1 billion

French drug maker Sanofi-Aventis will acquire U.S. biotech giant Genzyme for $20.1 billion, under an agreement the two companies announced Wednesday.

January 26, 2011
Watson seeks FDA approval for generic Welchol

Watson Pharmaceuticals is seeking regulatory approval for a generic drug for high cholesterol.

© 2013 Drug Store News. All Rights Reserved.